Cargando…
Long-Term Visual Outcomes for a Treat and Extend Anti-Vascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration
With the advent of anti-vascular endothelial growth factor (VEGF) therapy, clinicians are now focused on various treatment strategies to better control neovascular age-related macular degeneration (NVAMD), a leading cause of irreversible blindness. Herein, we retrospectively reviewed consecutive pat...
Autores principales: | Mrejen, Sarah, Jung, Jesse J., Chen, Christine, Patel, Samir N., Gallego-Pinazo, Roberto, Yannuzzi, Nicolas, Xu, Luna, Marsiglia, Marcela, Boddu, Sucharita, Freund, K. Bailey |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519796/ https://www.ncbi.nlm.nih.gov/pubmed/26239682 http://dx.doi.org/10.3390/jcm4071380 |
Ejemplares similares
-
Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
por: Yannuzzi, Nicolas A, et al.
Publicado: (2019) -
Recurrence of neovascular age-related macular degeneration after cessation of treat and extend regimen
por: Hirata, Yuki, et al.
Publicado: (2022) -
Type 1 neovascularization may confer resistance to geographic atrophy amongst eyes treated for neovascular age-related macular degeneration
por: Dhrami-Gavazi, Elona, et al.
Publicado: (2015) -
Macular neovascularization lesion type and vision outcomes in neovascular age-related macular degeneration: post hoc analysis of HARBOR
por: Freund, K. Bailey, et al.
Publicado: (2022) -
One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
por: Matsumoto, Hidetaka, et al.
Publicado: (2022)